Navigation Links
Pfizer Suspends Chronic Pain Studies in Tanezumab Clinical Trial Program; Some Studies Continue in Areas of Unmet Medical Need

NEW YORK, July 19 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) today announced, at the request of the U.S. Food and Drug Administration (FDA), the suspension of the chronic low back pain and painful diabetic peripheral neuropathy studies in the clinical program for the investigational compound tanezumab. Investigation of the compound continues in some areas of high unmet medical need, including cancer pain.

(Logo: )

(Logo: )

The FDA's request follows further consideration of reports of adverse events in osteoarthritis patients taking tanezumab, and the agency's concerns regarding the potential for such events in other patient populations in which the compound is being studied.  Pfizer announced the suspension of tanezumab studies in patients with osteoarthritis in a June 23 press release.  

For studies on clinical hold, recruitment of new patients and the dosing of existing patients are suspended.  

Pfizer will continue to work with the FDA to reach a common understanding about the appropriate scope of continued clinical investigation of tanezumab.

Pfizer Inc.: Working together for a healthier world™

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life.  We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals.  Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products.  Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.  Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.  For more than 150 years, Pfizer has worked to make a difference for all who rely on us.  To learn more about our commitments, please visit us at

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pfizer and SMC Collaborate on Liver Cancer
2. Pfizer to Present More Than 40 Abstracts on Pre-Clinical, Clinical and Outcomes Research at Alzheimers Association International Conference on Alzheimers Disease
3. Pfizer Inc and GoIndustry DoveBid Partner to Auction Surplus Equipment from R&D Facilities Across the United States
4. Pfizer Invites Public to View and Listen to Webcast of August 3 Conference Call With Analysts
5. Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg®
6. Pfizer And Epocrates Partner To Give Healthcare Providers Access To Medical Information Specialists For Medication Questions
7. Pfizer Appoints Mikael Dolsten President of Worldwide Research and Development
8. Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference
9. Pfizer Reigns Supreme After Patent Cliff as Humira Kicks Avastin off Top Spot
10. Gelesis Unveils Novel Non-Invasive Capsulated Device for Obesity and Presents Clinical Data; Appoints Former Pfizer R&D President to Board
11. Pfizers Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts
Post Your Comments:
(Date:11/30/2015)... 2015  Hanger, Inc. (NYSE: HGR ) (the ... terms of its previously announced consent solicitation (as amended ... aggregate principal amount 7⅛% Senior Notes due 2018 (the ... fees payable pursuant to the Consent Solicitation, (ii) the ... the expiration date of the Consent Solicitation.    ...
(Date:11/30/2015)... , Nov. 30, 2015  Precision Image Analysis ... is pleased to announce a dramatic expansion of ... services. Building on its ISO-9001:2008 certification for its ... comprehensive Core Lab protocols and procedures. This expansion ... research activities.  Their Core Lab services include design ...
(Date:11/30/2015)... and REHOVOT, Israel , ... specialty pharmaceutical company focused on acquiring and developing innovative ... announced the appointment of Keith A. Katkin ... Gregory J. Flesher , chief executive officer for ... building successful organizations.  As chairman, he will be able ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... Brenntag Specialties, Inc. (BSI) has ... the Nutraceutical Specialties products into oral solid dosage in the over the counter ... are pleased to announce our expanded distribution agreement with ASI.” said Steve Brauer, ...
(Date:11/30/2015)... ... November 30, 2015 , ... California-based i2i Systems, ... announced today that Michigan-based Family Health Center (FHC) has selected i2iTracks as their ... FHC was awarded the largest Affordable Care Act grant for Federally Qualified Health ...
(Date:11/30/2015)... ... November 30, 2015 , ... An inventor from Charlottesville, Va., is ... "My last baby had high blood pressure due to loud noises," she said, "so ... babies from noise pollution as well as radio waves and microwaves." , The baby ...
(Date:11/30/2015)... ... November 30, 2015 , ... In an interview with Andy Mitchell of Peconic ... on Long Island’s east end. During the broadcast, entitled “Eyes: the Window to the ... glaucoma and cataracts, and how a visit with his grandmother to her physician put ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... magazines and websites specializing in independent living, assisted living and all other retirement ... Alzheimer’s awareness and research remains a top priority. , So ...
Breaking Medicine News(10 mins):